Executive Director, GCP QA; Clinical Practice, Quality Assurance

Revolution Medicines is a late‑stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline includes RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

Executive Director of GCP QA is a senior leadership role that sets and executes the global GCP quality strategy across clinical development programs. The role ensures compliance with regulatory requirements, industry standards, and company policies governing clinical trials. It provides strategic oversight of GCP QA activities, leads a high‑performing QA team, governs contract research organizations, and promotes continuous improvement to uphold quality and patient safety.

• Develop and execute the global GCP QA strategy aligned with corporate objectives, regulatory requirements, and Rev Med SOPs.
• Serve as the Clinical QA Lead for global Phase 2/3 oncology studies, representing QA in governance forums and providing decision‑making oversight on GCP‑related matters.
• Establish and maintain GCP QA frameworks, including policies, procedures, systems, and risk‑based quality management (RBQM) to ensure compliance with global regulations (FDA, EMA, ICH).
• Provide end‑to‑end QA oversight of clinical studies, including review and approval of key study documents (protocols, monitoring plans, vendor oversight plans, quality agreements), Trial Master File quality and inspection readiness, GxP computerized systems and data integrity controls.
• Lead and oversee GCP audit and inspection activities (investigator sites, vendors, internal processes, regulatory inspections such as BIMO and PV), ensuring timely resolution of findings and CAPAs.
• Serve as the primary QA interface with global regulatory authorities, leading inspection strategy and representing the organization during health‑authority interactions.
• Drive global inspection readiness through structured planning, mock inspections, and cross‑functional preparedness activities to support successful regulatory submissions and approvals.
• Oversee vendor and CRO quality management, including selection, qualification, governance models, performance monitoring (KPIs), and compliance with quality agreements.
• Proactively identify and mitigate systemic quality risks across the clinical portfolio, influencing development strategies and ensuring effective escalation to senior leadership.
• Monitor, trend, and report quality metrics (KPIs, QTLs, TMF health, CAPAs), leveraging insights to drive continuous improvement and operational excellence.
• Provide QA oversight of pharmacovigilance activities, ensuring compliance with safety reporting requirements and vendor performance expectations.
• Partner cross‑functionally with Clinical Development, Clinical Operations, Regulatory Affairs, and Pharmacovigilance to drive quality, compliance, and continuous improvement.
• Drive innovation in QA through adoption of digital tools, advanced analytics, and modern risk‑based quality approaches.
• Build, scale, and lead a high‑performing global GCP QA organization, fostering a culture of quality, accountability, and operational excellence.
• Serve as a subject‑matter expert on GCP/GLP/PV regulations, advising senior leadership and influencing quality strategy across the organization.

• Advanced degree in life sciences, pharmacy, chemistry, or a related field (PhD, MS, or equivalent preferred).
• Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (FDA BIMO, EMA, MHRA, PMDA).
• Demonstrated experience interacting directly with global health authorities and leading inspection strategy and execution.
• Experience supporting late‑stage clinical development and regulatory submissions (e.g., NDA, MAA), preferably in oncology.
• Proven track record and relevant industry experience in leading GCP QA functions within a global organization, preferably in oncology.
• Strong knowledge of global GCP regulations, ICH guidelines, and…